Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOSTON-4 Phase IIa Study of Liposomal Cyclosporine A in Bronchiolitis Obliterans Syndrome after Allogeneic HSCT
2019-000718-13Phase 2Completed
- Sponsor
- Zambon
- Start
- Jun 2019
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of cyclosporine in Bronchiolitis Obliterans Syndrome (BOS), sponsored by Zambon. Primary endpoint: Primary tolerability and safety (first 4 weeks). Started Jun 2019; status: completed.
02
Drugs
cyclosporine
03
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Beyond the preview
Go deeper on 2019-000718-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000718-13.